Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Average

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month […]

Related Keywords

Baisong Mei , Gilmore Neil Oneill , Russell Investments Group Ltd , Barclays , Editas Medicine Inc , Lazard Asset Management , Nasdaq , Covestor Ltd , Jpmorgan Chase Co , Citigroup , Editas Medicine Company Profile , Editas Medicine , Get Free Report , Medicine Stock Down , Neilo Neill , Asset Management , Street Markets , Russell Investments Group , Investments Group , Get Free , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Credit , Medical , Ratings , Consensus ,